The Uromigos

401 Episoder

1. Episode 183: Oliver Sartor - The Uromigos Legends Series

   Publisert: 18.7.2022
2. Episode 182: ASCO Kidney Cancer Guidelines

   Publisert: 11.7.2022
3. Episode 181: Relapsed Germ Cell Tumours

   Publisert: 27.6.2022
4. Episode 180: Enzalutamide vs active surveillance in early prostate cancer

   Publisert: 20.6.2022
5. Episode 179: PSMA PET for Lutetium-177 in prostate cancer

   Publisert: 20.6.2022
6. Episode 178: ASCO 2022: Germline variants in men of African descent with prostate cancer

   Publisert: 7.6.2022
7. Episode 177: ASCO 2022: ENZAMET survival update

   Publisert: 5.6.2022
8. Episode 176: ASCO 2022: HER-2 ADCs in Bladder Cancer

   Publisert: 5.6.2022
9. Episode 175: ASCO 2022: Targeting the microbiome in renal cancer

   Publisert: 4.6.2022
10. Episode 174: ASCO 2022: Cell free DNA as a biomarker in bladder cancer

    Publisert: 3.6.2022
11. Episode 173: ASCO 2022: The Atlantis Trial - maintenance cabozantinib in bladder cancer

    Publisert: 3.6.2022
12. Episode 172: ASCO 2022: Adjuvant everolimus in renal cancer

    Publisert: 3.6.2022
13. Episode 171: Antibody drug conjugates in bladder cancer: managing adverse effects

    Publisert: 23.5.2022
14. Episode 170: APCCC Meeting Summary

    Publisert: 16.5.2022
15. Episode 169: The Uromigos Paper of the Month - Novel neoadjuvant approaches in UC

    Publisert: 9.5.2022
16. Episode 168: Mechanisms of response to PD1 therapy in renal cancer

    Publisert: 2.5.2022
17. Episode 167: Highlights from EIKCS oral session

    Publisert: 22.4.2022
18. Episode 166: Prostate cancer debate: doublet vs triplet first line therapy

    Publisert: 18.4.2022
19. Episode 165: Paper of the Month - ENZAMET quality of life data

    Publisert: 6.4.2022
20. Episode 164: Paper of the Month - what can we learn from R3 ipilimumab/nivolumab in gastric cancer

    Publisert: 1.4.2022